Pharmaceutical Innovation After World War Ii From Rational Drug Discovery To Biopharmaceuticals
Download Pharmaceutical Innovation After World War Ii From Rational Drug Discovery To Biopharmaceuticals full books in PDF, epub, and Kindle. Read online free Pharmaceutical Innovation After World War Ii From Rational Drug Discovery To Biopharmaceuticals ebook anywhere anytime directly on your device. Fast Download speed and no annoying ads. We cannot guarantee that every ebooks is available!
Author | : Apostolos Zarros |
Publisher | : Frontiers Media SA |
Total Pages | : 137 |
Release | : 2019-11-27 |
Genre | : |
ISBN | : 2889632237 |
This eBook is a collection of articles from a Frontiers Research Topic. Frontiers Research Topics are very popular trademarks of the Frontiers Journals Series: they are collections of at least ten articles, all centered on a particular subject. With their unique mix of varied contributions from Original Research to Review Articles, Frontiers Research Topics unify the most influential researchers, the latest key findings and historical advances in a hot research area! Find out more on how to host your own Frontiers Research Topic or contribute to one as an author by contacting the Frontiers Editorial Office: frontiersin.org/about/contact.
Author | : Bruce Rasmussen |
Publisher | : Edward Elgar Publishing |
Total Pages | : 335 |
Release | : 2010-01-01 |
Genre | : Business & Economics |
ISBN | : 1849805512 |
The processes of discovery, testing and distribution of new medicines have undergone radical change in recent decades, from a focus on small molecule drugs to biomedicine and related technologies. Bruce Rasmussen very effectively draws upon modern theories of the firm, data analysis, and case studies to provide important insights into the consequences of this change. He offers convincing evidence that contradicts the widely-held view that the biopharmaceutical sector has not generated considerable economic value. Frank R. Lichtenberg, Columbia University, US Bio- and pharmaceutical industry discovery is a distressed asset today. Why? Bruce Rasmussen s book is a timely and very informative work, building on rich data sources and extensive economic research, on a subject of concern to us all. Is medicine discovery in permanent decline? Are the biotechnology and traditional pharma groups on a collision course, will the traditional group absorb the new, will integration take place, will a new discovery model emerge? I commend Bruce s book to all who wish to understand what is happening. David W. Anstice, Merck & Co., Inc. This path-breaking book addresses the ongoing implications for traditional pharmaceutical companies and biopharmaceutical start-ups of the realignment of the industry knowledge-base. The theoretical approach draws on the modern theory of the firm and related ideas in order to better define the concept of the business model, which is employed to guide the case studies and empirical analysis in the book. The author shows that while traditional pharmaceutical companies have successfully adjusted their business models to meet the challenges of biotechnology, biopharmaceutical start-ups have experienced more problems. Despite the poor financial performance of the vast majority of these firms, the biopharmaceutical sector as a whole has created significant value. However, this has been captured disproportionately by a handful of large, fully-integrated biopharmaceutical firms and, to a lesser extent, by the largest dozen pharmaceutical companies. This highly focused book will be a captivating read for innovation and biopharmaceutical industry analysts, as well as advisers formulating policies to support the development of the biopharmaceutical sector. Academics working on innovation and biotechnology, as well as scientists engaged in research in the life sciences, will also find this book of particular interest.
Author | : Alexander Schuhmacher |
Publisher | : John Wiley & Sons |
Total Pages | : 508 |
Release | : 2016-01-12 |
Genre | : Science |
ISBN | : 3527693416 |
This practical guide for advanced students and decision-makers in the pharma and biotech industry presents key success factors in R&D along with value creators in pharmaceutical innovation. A team of editors and authors with extensive experience in academia and industry and at some of the most prestigious business schools in Europe discusses in detail the innovation process in pharma as well as common and new research and innovation strategies. In doing so, they cover collaboration and partnerships, open innovation, biopharmaceuticals, translational medicine, good manufacturing practice, regulatory affairs, and portfolio management. Each chapter covers controversial aspects of recent developments in the pharmaceutical industry, with the aim of stimulating productive debates on the most effective and efficient innovation processes. A must-have for young professionals and MBA students preparing to enter R&D in pharma or biotech as well as for students on a combined BA/biomedical and natural sciences program.
Author | : Rifat A. Atun |
Publisher | : World Scientific |
Total Pages | : 153 |
Release | : 2007 |
Genre | : Business & Economics |
ISBN | : 9812770976 |
Innovation is at the heart of all advances and has the capacity to solve problems facing humanity. Societies which have turned away from innovation and technological development have failed in their ability to support their populations. Understanding the nature of innovation in the life sciences and in particular healthcare, how it operates, what enables and hinders it is therefore of great importance to meeting the challenges ahead. This book, originally and concurrently published in the International Journal of Innovation Management, Vol. 11, No. 2, 2007, offers the latest research and insights concerning innovation in the biopharmaceutical industry.
Author | : Oliver Gassmann |
Publisher | : Springer Science & Business Media |
Total Pages | : 194 |
Release | : 2008-02-19 |
Genre | : Business & Economics |
ISBN | : 3540776362 |
Pharmaceutical giants have been doubling their investments in drug development, only to see new drug approvals to remain constant for the past decade. This book investigates and highlights a set of proactive strategies, aimed at generating sustainable competitive advantage for its protagonists based on value-generating business practices. We focus on three sources of pharmaceutical innovation: new management methods in the drug development pipeline, new technologies as enablers for cutting-edge R&D, and new forms of internationalisation, such as outside-in innovation in the early phases of R&D.
Author | : Alfonso Gambardella |
Publisher | : Cambridge University Press |
Total Pages | : 236 |
Release | : 1995-03-09 |
Genre | : Business & Economics |
ISBN | : 0521451183 |
This book examines an increasingly important phenomenon for competitiveness and innovation in industry: namely, the growing use of scientific principles in industrial research. Industrial innovation still arises from systematic trial-and-error experiments with many designs and objects, but these experiments are now being guided by a more rational understanding of phenomena. This has important implications for market structure, firm strategies, and competition. Science and innovation focuses on the pharmaceutical industry. It discusses the changes that the notable advances in the life sciences in the 1980s have brought to the strategies of drug companies, the organization of their internal research, their relationships with scientific institutions, the division of labor between large pharmaceutical firms and small research-intensive suppliers, the productivity of drug discovery, and the productivity of R&D.
Author | : Burcu KiliƧ |
Publisher | : Edward Elgar Publishing |
Total Pages | : 285 |
Release | : 2014-07-31 |
Genre | : Law |
ISBN | : 1782544135 |
Boosting Pharmaceutical Innovation In The Post-TRIPS Era investigates the concept of innovation and illustrates the crucial role that patent strategies play within processes of pharmaceutical innovation. Drawing on extensive country and company case studies, it identifies the key issues relevant to the revival of local pharmaceutical industries.
Author | : Takuji Hara |
Publisher | : Edward Elgar Publishing |
Total Pages | : 296 |
Release | : 2003 |
Genre | : Business & Economics |
ISBN | : |
Innovation in the Pharmaceutical Industry traces the discovery and development of drugs in Japan and the UK both historically and sociologically. It includes sixteen case studies of major pharmaceutical developments in the twentieth century, encompassing, amongst others, beta-blockers, beta-stimulants, inhaled steroids and histamine H2-antagonists. The book illustrates that the four stages of drug development - namely compound, application, organisational authorisation and market - are interactively shaped by heterogeneous actors and institutions. The book also identifies three different types of pharmaceutical development - paradigmatic innovation, application innovation and modification-based innovation, all with distinguishable features in the drug development process. Finally, several historical, structural and cultural factors influencing the shaping of medicines are revealed by the comparison between British and Japanese drug innovation. Addressing a number of practical implications for the promotion of the pharmaceutical industry, this book will be of enormous interest to students, researchers and academics specialising in science and technology, and the management of technology and innovation. Practitioners, managers, and policy planners within the pharmaceutical industry will also deem this book invaluable.
Author | : Oliver Gassmann |
Publisher | : Springer |
Total Pages | : 179 |
Release | : 2018-04-29 |
Genre | : Business & Economics |
ISBN | : 9783319668321 |
Pharmaceutical giants have been doubling their investments in drug development, only to see new drug approvals to remain constant for the past decade. This book investigates and highlights a set of proactive strategies, aimed at generating sustainable competitive advantage for its protagonists based on value-generating business practices. We focus on three sources of pharmaceutical innovation: new management methods in the drug development pipeline, new technologies as enablers for cutting-edge R&D, and new forms of internationalisation, such as outside-in innovation in the early phases of R&D.
Author | : Franco Malerba |
Publisher | : Cambridge University Press |
Total Pages | : 537 |
Release | : 2004-08-12 |
Genre | : Business & Economics |
ISBN | : 1139454161 |
This volume provides a novel way of examining innovation in sectors by proposing the framework of sectoral systems of innovation. It analyses the innovation process, the factors affecting innovation, the changing boundaries and transformation of sectors, and the determinants of the innovation performance of firms and countries in different sectors.